Kiora Pharmaceuticals (KPRX) & Its Competitors Head-To-Head Review

Kiora Pharmaceuticals (NASDAQ:KPRX) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Kiora Pharmaceuticals to similar businesses based on the strength of its dividends, analyst recommendations, institutional ownership, valuation, risk, profitability and earnings.

Insider and Institutional Ownership

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 0.5% of Kiora Pharmaceuticals shares are held by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Kiora Pharmaceuticals and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Kiora Pharmaceuticals	$16.02 million	-$10.84 million	-0.49
Kiora Pharmaceuticals Competitors	$3.55 billion	$3.19 billion	561.66

Kiora Pharmaceuticals’ peers have higher revenue and earnings than Kiora Pharmaceuticals. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Kiora Pharmaceuticals has a beta of -0.13, indicating that its share price is 113% less volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals’ peers have a beta of -0.13, indicating that their average share price is 113% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Kiora Pharmaceuticals and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1	0	0	0	1.00
Kiora Pharmaceuticals Competitors	7840	13794	25805	1039	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 24.69%. Given Kiora Pharmaceuticals’ peers stronger consensus rating and higher possible upside, analysts plainly believe Kiora Pharmaceuticals has less favorable growth aspects than its peers.

Profitability

This table compares Kiora Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-81.61%	-55.29%
Kiora Pharmaceuticals Competitors	-2,400.69%	-221.80%	-15.58%

Summary

Kiora Pharmaceuticals peers beat Kiora Pharmaceuticals on 9 of the 13 factors compared.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals is a clinical-stage biotechnology company focused on developing treatments for retinal and other eye diseases. Its research centers on therapies intended to address conditions with limited treatment options. The company’s pipeline includes KIO-301, an investigational photoswitch designed to restore light sensitivity in people with retinitis pigmentosa and other inherited retinal degenerative diseases. Kiora is also developing KIO-101, an investigational therapy for inflammatory eye diseases, including non-infectious uveitis.